Profound Medical Reports Strong Q1 Growth, Improved Profitability, and Key Humana Payer Coverage for TULSA Procedure

summarizeSummary

Profound Medical Corp. announced robust first-quarter 2026 financial results, featuring 104% revenue growth and a 34% reduction in net loss, alongside a significant expansion of market access with Humana now covering its TULSA Procedure.

check_boxKey Events

• Strong Q1 Financial Performance

  Revenue grew 104% year-over-year to $5.3 million, with net loss improving by 34% to $7.0 million, or $0.19 per common share.

• Major Payer Coverage Expansion

  Humana, a national payor, has become the first to cover the TULSA Procedure, adding approximately 8.5 million covered lives and significantly increasing market access for the company's flagship product.

• Positive Full-Year 2026 Guidance

  The company projects total revenue of approximately $25 million for full-year 2026, representing 56% year-over-year growth, with gross margins expected at 70% or higher.

• Clinical Trial Progress

  The Level 1 post-market CAPTAIN randomized controlled trial announced superiority on its primary safety endpoint for the TULSA Procedure, with additional clinical outcomes anticipated later this year.

auto_awesomeAnalysis

This filing highlights Profound Medical's strong operational execution, marked by triple-digit revenue growth and improved profitability. The announcement of Humana, a major national payor, covering the TULSA Procedure is a critical development, significantly expanding patient access and de-risking future revenue streams. This commercial milestone, combined with positive full-year guidance and ongoing clinical trial success, positions the company for continued growth and reinforces its market position in interventional MRI procedures. Investors should monitor the continued rollout of payer coverage and further clinical outcomes from the CAPTAIN trial.